Scilex 8-K: Common Stock Par Value $0.0001, Warrants $11.50

TL;DR

**Scilex filed an 8-K clarifying common stock par value and warrant exercise price, a routine update.**

AI Summary

Scilex Holding Company filed an 8-K on January 2, 2024, to update its corporate information, specifically noting its common stock has a par value of $0.0001 per share and warrants are exercisable at $11.50 per share. This filing is a routine update, indicating no immediate financial changes but providing clarity on the company's capital structure. For investors, this matters as it confirms the foundational details of their shares and warrants, which are crucial for understanding potential dilution or exercise value.

Why It Matters

This filing provides updated, specific details about Scilex Holding Company's common stock par value and warrant exercise price, which are fundamental to understanding the company's capital structure and potential future equity changes.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing updating corporate information and does not indicate any new financial risks or operational changes.

Analyst Insight

A smart investor would note these updated details for their records, but recognize this filing is administrative and does not signal any immediate investment action or change in company fundamentals.

Key Numbers

• $0.0001 — Common Stock Par Value (The stated par value per share for Scilex Holding Company's common stock.)
• $11.50 — Warrant Exercise Price (The price at which each warrant can be exercised to purchase one share of common stock.)

Key Players & Entities

• Scilex Holding Company (company) — the registrant filing the 8-K
• $0.0001 (dollar_amount) — par value per share of common stock
• $11.50 (dollar_amount) — exercise price per share for warrants
• January 2, 2024 (date) — date of earliest event reported and filing date

FAQ

Key Financial Figures

• $0.0001 — ich registered Common stock, par value $0.0001 per share SCLX The Nasdaq Stock Mar
• $11.50 — mon stock, each at an exercise price of $11.50 per share SCLXW The Nasdaq Stock Ma
• $145.0 million — December 31, 2023 were in the range of $145.0 million to $150.0 million, compared to $96.0 mi
• $150.0 m — were in the range of $145.0 million to $150.0 million, compared to $96.0 million for th
• $96.0 million — million to $150.0 million, compared to $96.0 million for the fiscal year ended December 31,
• $46.0 million — December 31, 2023 were in the range of $46.0 million to $52.0 million, compared to $38.0 mil
• $52.0 m — 3 were in the range of $46.0 million to $52.0 million, compared to $38.0 million for th
• $38.0 million — 0 million to $52.0 million, compared to $38.0 million for the fiscal year ended December 31,
• $150.0 million — December 31, 2023 were in the range of $150.0 million to $155.0 million, compared to $96.0 mi
• $155.0 m — were in the range of $150.0 million to $155.0 million, compared to $96.0 million for th
• $46.5 million — December 31, 2023 were in the range of $46.5 million to $52.5 million, compared to $38.0 mil
• $52.5 m — 3 were in the range of $46.5 million to $52.5 million, compared to $38.0 million for th

Filing Documents

• d678133d8k.htm (8-K) — 30KB
• d678133dex991.htm (EX-99.1) — 21KB
• g678133g1231000103871.jpg (GRAPHIC) — 5KB
• 0001193125-24-000300.txt ( ) — 224KB
• sclx-20240102.xsd (EX-101.SCH) — 4KB
• sclx-20240102_def.xml (EX-101.DEF) — 14KB
• sclx-20240102_lab.xml (EX-101.LAB) — 23KB
• sclx-20240102_pre.xml (EX-101.PRE) — 14KB
• d678133d8k_htm.xml (XML) — 6KB

02

Item 2.02. Results of Operations and Financial Condition. Scilex Holding Company (the "Company") is providing certain preliminary unaudited financial results for the fiscal year ended December 31, 2023 based on currently available information. The Company's independent auditor has not reviewed or audited these preliminary estimated financial results. The Company's actual results may differ materially from these preliminary financial results, and may be outside the estimated ranges. This preliminary financial data has been prepared by and is the responsibility of the Company. The Company has not fully completed its review of these preliminary financial results for the fiscal year ended December 31, 2023. The Company estimates that: ZTlido gross sales for the fiscal year ended December 31, 2023 were in the range of $145.0 million to $150.0 million, compared to $96.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 51% to 56%. ZTlido net sales for the fiscal year ended December 31, 2023 were in the range of $46.0 million to $52.0 million, compared to $38.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 21% to 37%. Total product gross sales for the fiscal year ended December 31, 2023 were in the range of $150.0 million to $155.0 million, compared to $96.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 56% to 61%. Total product net sales for the fiscal year ended December 31, 2023 were in the range of $46.5 million to $52.5 million, compared to $38.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 22% to 38%. On January 2, 2024, the Company issued a press release that included certain preliminary unaudited financial results for the twelve months ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is in

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated January 2, 2024. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SCILEX HOLDING COMPANY By: /s/ Jaisim Shah Name: Jaisim Shah Title: Chief Executive Officer & President Date: January 2, 2024 3

View Full Filing

View this 8-K filing on SEC EDGAR